SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+10.93%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$574M
AUM Growth
+$574M
(-8.1%)
Cap. Flow
-$49.9M
Cap. Flow
% of AUM
-8.69%
Top 10 Holdings %
Top 10 Hldgs %
40.42%
Holding
159
New
26
Increased
30
Reduced
26
Closed
52
Top Buys
| 1 |
SHPG
Shire pic
SHPG
|
$16.4M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$14.3M |
| 3 |
NMTR
9 Meters Biopharma, Inc. Common Stock
NMTR
|
$12.3M |
| 4 |
Amicus Therapeutics
FOLD
|
$11.2M |
| 5 |
Merck
MRK
|
$8.44M |
Top Sells
| 1 |
CEL
Cellcom Israel, Ltd.
CEL
|
$14M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$12.9M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$10.2M |
| 4 |
Sarepta Therapeutics
SRPT
|
$10.1M |
| 5 |
RXDX
Ignyta, Inc.
RXDX
|
$9.19M |
Sector Composition
| 1 | Healthcare | 86.99% |
| 2 | Technology | 5.23% |
| 3 | Communication Services | 1.51% |
| 4 | Financials | 1.35% |
| 5 | Consumer Discretionary | 1.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merck
MRK
$210B
| $31.6M | 4.8% | 580,000 +155,000 | +36% | +$8.44M |
|
|
SHPG
2
DELISTED
Shire pic
SHPG
| $29.4M | 4.46% | 196,500 +110,000 | +127% | +$16.4M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $28.5M | 4.32% | 319,000 +10,000 | +3% | +$892K |
|
|
4
Amicus Therapeutics
FOLD
$2.34B
| $27.8M | 4.21% | 1,845,704 +745,704 | +68% | +$11.2M |
|
5
Viatris
VTRS
$12.3B
| $23.6M | 3.59% | 574,000 -182,449 | -24% | -$7.51M |
|
6
Pfizer
PFE
$141B
| $20.9M | 3.18% | 590,000 +200,000 | +51% | +$7.1M |
|
7
GSK
GSK
$79.9B
| $19.5M | 2.97% | 500,000 +50,000 | +11% | +$1.95M |
|
|
8
Sarepta Therapeutics
SRPT
$1.78B
| $18.4M | 2.8% | 248,997 -136,000 | -35% | -$10.1M |
|
9
Biogen
BIIB
$19.4B
| $17.8M | 2.7% | 65,000 -9,200 | -12% | -$2.52M |
|
|
10
Regeneron Pharmaceuticals
REGN
$61.5B
| $14.3M | 2.17% | +41,500 | New | +$14.3M |
|
|
NMTR
11
DELISTED
9 Meters Biopharma, Inc. Common Stock
NMTR
| $12.3M | 1.86% | +980,502 | New | +$12.3M |
|
12
Clearside Biomedical
CLSD
$28.9M
| $11.1M | 1.68% | 1,030,000 +580,000 | +129% | +$6.22M |
|
|
CLLS
13
Cellectis
CLLS
$258M
| $10.7M | 1.62% | 339,367 | – | – |
|
|
AGN
14
DELISTED
Allergan plc
AGN
| $10.1M | 1.53% | 60,000 | – | – |
|
|
OBSV
15
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $10.1M | 1.53% | 745,197 +197,500 | +36% | +$2.66M |
|
|
ALXN
16
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $9.14M | 1.39% | 82,000 -38,000 | -32% | -$4.24M |
|
|
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
| $8.87M | 1.35% | 168,000 +10,000 | +6% | +$528K |
|
|
ADMS
18
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $8.02M | 1.22% | 335,500 +195,000 | +139% | +$4.66M |
|
|
LJPC
19
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $7.74M | 1.18% | 260,000 +35,000 | +16% | +$1.04M |
|
20
Aldeyra Therapeutics
ALDX
$351M
| $7.57M | 1.15% | 1,009,131 -35,000 | -3% | -$262K |
|
|
MLNX
21
DELISTED
Mellanox Technologies, Ltd.
MLNX
| $7.31M | 1.11% | 100,279 +26,833 | +37% | +$1.95M |
|
|
IMMU
22
DELISTED
Immunomedics Inc
IMMU
| $7.01M | 1.06% | 480,000 +250,000 | +109% | +$3.65M |
|
23
Viking Therapeutics
VKTX
$3.04B
| $6.96M | 1.06% | 1,592,416 -552,884 | -26% | -$2.42M |
|
|
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
| $6.61M | 1% | 405,000 | – | – |
|
|
ARQL
25
DELISTED
Arqule Inc
ARQL
| $6.52M | 0.99% | +2,264,136 | New | +$6.52M |
|